inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 110.35401/2541-9897-2024-9-4-126-135inovmed-979Research ArticleОБЗОРЫREVIEWSПротективный потенциал ингибиторов натрий-глюкозного котранспортера 2 типа в клинике внутренних болезней (часть 1)Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)https://orcid.org/0000-0002-5383-8355АвагимянА. А.AvagimyanA. A.

Авагимян Ашот Арманович - к. м. н., научный сотрудник Института сердечно-сосудистых исследований при Всемирной организации здравоохранения, Исфаханский университет медицинских наук; докторант-исследователь кафедры доказательной медицины, Медицинский институт, РУДН им. Патриса Лумумбы.

ул. Муштака 3, Исфахан, 8158388994

Ashot A. Avagimyan - Cand. Sci. (Med.), Researcher, Institute of Cardiovascular Research, Isfahan University of Medical Sciences (Isfahan, Iran); Doctoral Candidate, Researcher, Department of Evidence-Based Medicine, Institute of Medicine, Patrice Lumumba Peoples’ Friendship University of Russia.

Mushtaq 3rd St, Isfahan, 8158388994

dr.ashotavagimyan@gmail.comhttps://orcid.org/0000-0003-2495-2957ШейбаниМ.SheibaniM.

Шейбани Мохаммад - PhD, ассистент кафедры фармакологии, научный сотрудник Исследовательского центра лекарств им. Рази, школа медицины.

Тегеран

Mohammad Sheibani - PhD, Assistant Professor at the Department of Pharmacology, Researcher at Razi Drug Research Institute, School of Medicine, Iran University of Medical Sciences.

Tehran

https://orcid.org/0000-0001-7140-0739ТрофименкоА. И.TrofimenkoA. I.

Трофименко Артем Иванович - к. м. н., доцент кафедры патологической физиологии.

Краснодар

Artem I. Trofimenko - Cand. Sci. (Med.), Associate Professor at the Pathological Physiology Department, Kuban State Medical University.

Krasnodar

https://orcid.org/0000-0002-9743-0394ЛысовЕ. Е.LysovE. E.

Лысов Евгений Евгеньевич - ассистент кафедры патологической физиологии.

Краснодар

Evgenii E. Lysov - Assistant Professor at the Pathological Physiology Department, Kuban State Medical University.

Krasnodar

https://orcid.org/0000-0001-6084-7025ХамидоваФ. М.KhamidovaF. M.

Хамидова Фарида Муиновна - д. м. н., доцент, заведующая кафедрой патологической анатомии.

Самарканд

Farida M. Khamidova - Dr. Sci. (Med.), Associate Professor, Head of the Pathological Anatomy Department, Samarkand State Medical University.

Samarkand

https://orcid.org/0000-0002-9642-7740АзнаурянА. З.AznauryanA. Z.

Азнаурян Анаит Захаровна - к. б. н., доцент кафедры гистологии.

Ереван

Anahit Z. Aznauryan - Cand. Sci. (Bio.), Associate Professor at the Histology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0000-0001-7696-0639СукиасянЛ. М.SukiasyanL. M.

Сукиасян Лилит Магаковна - к. м. н., научный сотрудник центральной исследовательской лаборатории.

Ереван

Lilit M. Sukiasyan - Cand. Sci. (Bio.), Researcher, Central Research Laboratory, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0002-0486-0844СаакянК. Т.SahakyanK. T.

Саакян Кармен Тельмановна - д. б. н., профессор, заведующая кафедрой гистологии.

Ереван

Karmen T. Sahakyan - Dr. Sci. (Bio.), Professor, Head of the Histology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0006-5525-6566ГеворгянТ. Р.GevorgyanT. R.

Геворгян Тамара Рубеновна - к. м. н., доцент кафедры детской офтальмологии.

Ереван

Tamara R. Gevorgyan - Cand. Sci. (Bio.), Associate Professor at the Pediatric Ophthalmology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0006-3124-4157ТатоянМ. Р.TatoyanM. R.

Татоян Марина Размиковна - д. б. н., профессор кафедры гистологии.

Ереван

Marina R. Tatoyan - Dr. Sci. (Bio.), Professor at the Histology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0005-1908-1116МкртчянГ. Л.MkrtchyanG. L.

Мкртчян Гаяне Левановна - к. б. н., доцент кафедры гистологии.

Ереван

Gayane L. Mkrtchyan - Cand. Sci. (Bio.), Associate Professor at the Histology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0008-9572-6598МелтонянГ. Л.MeltonyanG. L.

Мелтонян Гоарик Левоновна - к. б. н., доцент кафедры гистологии.

Ереван

Goharik L. Meltonyan - Cand. Sci. (Bio.), Associate Professor at the Histology Department, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0009-0006-4944-5707ПетросянА. Р.PetrosyanA. R.

Петросян Анна Рубеновна - преподаватель кафедры патологической анатомии и клинической морфологии.

Ереван

Anna R. Petrosyan - Lecturer at the Department of Pathological Anatomy and Clinical Morphology, Yerevan State Medical University after M. Heratsi.

Yerevan

https://orcid.org/0000-0003-0532-148XМартемьяноваЛ. А.MartemyanovaL. A.

Мартемьянова Людмила Александровна - к. м. н., доцент, заведующая кафедрой патологической анатомии.

Гомель

Ludmila A. Martemyanova - Cand. Sci. (Med.), Associate Professor, Head of the Pathological Anatomy Department, Gomel State Medical University.

Gomel

https://orcid.org/0000-0001-6787-0893ПетросянР. Р.PetrosyanR. R.

Петросян Рузанна Рубеновна - PhD, MHPE, преподаватель анатомии, школа медицины им. Гилберта и Роуз-Мэри Шагури.

Бейрут

Ruzanna R. Petrosyan - PhD, MHPE, Assistant Professor (Anatomy), Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University.

Beirut

https://orcid.org/0000-0002-9457-8879УразоваО. И.UrazovaO. I.

Уразова Ольга Ивановна - д. м. н., профессор, член-корреспондент РАН, заведующая кафедрой патофизиологии.

Томск

Olga I. Urazova - Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Pathophysiology Department, Siberian State Medical University.

Tomsk

https://orcid.org/0000-0002-4165-804XПогосоваН. В.PogosovaN. V.

Погосова Нана Вачиковна - д. м. н., профессор, заместитель генерального директора по науке и профилактической кардиологии, НМИЦ кардиологии им. акад. Е.И. Чазова; заведующая кафедрой доказательной медицины, Медицинский институт, РУДН им. Патриса Лумумбы.

Москва

Nana V. Pogosova - Dr. Sci. (Med.), Professor, Deputy General Director for Science and Preventive Cardiology, National Medical Research Centre of Cardiology named after Academician Chazov; Head of the Department of Evidence-Based Medicine, Institute of Medicine, Patrice Lumumba Peoples’ Friendship University of Russia.

Moscow

https://orcid.org/0000-0002-8352-0540СаррафзадеганН.SarrafzadeganN.

Саррафзадеган Низал - PhD, почетный профессор, директор Исфаханского центра сердечно-сосудистых исследований, Институт сердечно-сосудистых исследований при Всемирной организации здравоохранения.

Исфахан

Nizal Sarrafzadegan - PhD, Distinguished Professor, Director of the Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences.

Isfahan

Исфаханский университет медицинских наук; Российский университет дружбы народов им. П. ЛумумбыИранIsfahan University of Medical Sciences; Patrice Lumumba Peoples’ Friendship University of RussiaIslamic Republic of IranИранский университет медицинских наукИранIran University of Medical SciencesIslamic Republic of IranКубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian FederationСамаркандский государственный медицинский университетУзбекистанSamarkand State Medical UniversityUzbekistanЕреванский государственный медицинский университет им. М. ГерациАрменияYerevan State Medical University after M. HeratsiArmeniaГомельский государственный медицинский университетБеларусьGomel State Medical UniversityBelarusЛивано-Американский университетЛиванLebanese American UniversityLebanonСибирский государственный медицинский университетРоссияSiberian State Medical UniversityRussian FederationРоссийский университет дружбы народов им. П. Лумумбы; Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. ЧазоваРоссияPatrice Lumumba Peoples’ Friendship University of Russia; National Medical Research Centre of Cardiology named after Academician E.I. ChazovRussian FederationИсфаханский университет медицинских наукИранIsfahan University of Medical SciencesIslamic Republic of Iran20243012202404126135Copyright © Авагимян А.А., Шейбани М., Трофименко А.И., Лысов Е.Е., Хамидова Ф.М., Азнаурян А.З., Сукиасян Л.М., Саакян К.Т., Геворгян Т.Р., Татоян М.Р., Мкртчян Г.Л., Мелтонян Г.Л., Петросян А.Р., Мартемьянова Л.А., Петросян Р.Р., Уразова О.И., Погосова Н.В., Саррафзадеган Н., 20242024Авагимян А.А., Шейбани М., Трофименко А.И., Лысов Е.Е., Хамидова Ф.М., Азнаурян А.З., Сукиасян Л.М., Саакян К.Т., Геворгян Т.Р., Татоян М.Р., Мкртчян Г.Л., Мелтонян Г.Л., Петросян А.Р., Мартемьянова Л.А., Петросян Р.Р., Уразова О.И., Погосова Н.В., Саррафзадеган Н.Avagimyan A.A., Sheibani M., Trofimenko A.I., Lysov E.E., Khamidova F.M., Aznauryan A.Z., Sukiasyan L.M., Sahakyan K.T., Gevorgyan T.R., Tatoyan M.R., Mkrtchyan G.L., Meltonyan G.L., Petrosyan A.R., Martemyanova L.A., Petrosyan R.R., Urazova O.I., Pogosova N.V., Sarrafzadegan N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/979

Ингибиторы натрий-глюкозного котранспортера 2 типа (SGLT2i) вошли в клиническую практику как революционный класс пероральных сахаропонижающих препаратов. По мере накопления клинических данных были обнаружены их долговременные защитные эффекты в отношении многих органов и тканей. Защитный потенциал SGLT2i гораздо шире, чем классическая концепция контроля глюкозы и состоит из целого конгломерата плейотропных эффектов.

Целью данной статьи является предоставление описательного обзора плейотропного терапевтического потенциала SGLT2i. В первой части обзора литературы рассматривается использование SGLT2i в кардиологии и нефрологии.

Таким образом, использование SGLT2i представляет собой инновационный подход к улучшению качества жизни пациентов и течения как сердечной недостаточности, так и хронической болезни почек, независимо от фракции выброса левого желудочка и наличия сахарного диабета 2 типа.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.

SGLT2iкардиопротекциянефропротекциядапаглифлозинэмпаглифлозинSGLT2icardioprotectionnephroprotectiondapagliflozinempagliflozinReferencesIdowu A, Adebolu O, Wattanachayakul P, et al. Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024;49(8):102648. PMID: 38759767. https://doi.org/10.1016/j.cpcardiol.2024.102648Idowu A, Adebolu O, Wattanachayakul P, et al. Cardiovascular outcomes of sodium-glucose Co-transporter 2 inhibitors use after myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024;49(8):102648. PMID: 38759767. https://doi.org/10.1016/j.cpcardiol.2024.102648Patoulias D. SGLT-2 inhibitors beneficial effects on ventricular repolarization may be protective against atrial fibrillation occurrence. Acta Cardiol Sin. 2021;37(3):323. PMID: 33976519. PMCID: PMC8107699. https://doi.org/10.6515/ACS.202105_37(3).20210313APatoulias D. SGLT-2 inhibitors beneficial effects on ventricular repolarization may be protective against atrial fibrillation occurrence. Acta Cardiol Sin. 2021;37(3):323. PMID: 33976519. PMCID: PMC8107699. https://doi.org/10.6515/ACS.202105_37(3).20210313AJasleen B, Vishal GK, Sameera M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus. 2023;15(1):e33939. PMID: 36819350. PMCID: PMC9937770. https://doi.org/10.7759/cureus.33939Jasleen B, Vishal GK, Sameera M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: benefits versus risk. Cureus. 2023;15(1):e33939. PMID: 36819350. PMCID: PMC9937770. https://doi.org/10.7759/cureus.33939Терещенко С.Н., Шестакова М.В., Агеев Ф.Т. и др. Целесообразность назначения дапаглифлозина для профилактики неблагоприятных исходов хронической сердечной недостаточности у пациентов со сниженной фракцией выброса. Резолюция совета экспертов. Российский кардиологический журнал. 2020;25(5):3919. https://doi.org/10.15829/1560-4071-2020-3919Tereshchenko SN, Shestakova MV, Ageev FT, et al. Rationale for dapagliflozin administration for the prevention of adverse out-comes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology. 2020;25(5):3919. (In Russ.). https://doi.org/10.15829/1560-4071-2020-3919Кобалава Ж.Д., Лазарев П.В., Виллевальде С.В. ингибиторы SGLT2: обоснование и перспективы применения при сердечной недостаточности. Кардиология. 2018;58(2):42–54. PMID: 29466200. https://doi.org/10.18087/cardio.2018.2.10087Kobalava ZD, Lazarev PV, Villevalde SV. SGLT2 inhibitors: rationale and perspectives of use in heart failure. Kardiologiia. 2018;58(2):42–54. (In Russ.). PMID: 29466200. https://doi.org/10.18087/cardio.2018.2.10087Faluk M, Wardhere A, Thakker R, Khan FA. SGLT2 inhibitors in heart failure with preserved ejection fraction. Curr Probl Cardiol. 2024;49(3):102388. PMID: 38184133. https://doi.org/10.1016/j.cpcardiol.2024.102388Faluk M, Wardhere A, Thakker R, Khan FA. SGLT2 inhibitors in heart failure with preserved ejection fraction. Curr Probl Cardiol. 2024;49(3):102388. PMID: 38184133. https://doi.org/10.1016/j.cpcardiol.2024.102388Avagimyan A, Sheibani M, Pogosova N, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331. PMID: 37666280. https://doi.org/10.1016/j.ijcard.2023.131331Avagimyan A, Sheibani M, Pogosova N, et al. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy. Int J Cardiol. 2023;391:131331. PMID: 37666280. https://doi.org/10.1016/j.ijcard.2023.131331Gajewska A, Wasiak J, Sapeda N, Młynarska E, Rysz J, Franczyk B. SGLT2 inhibitors in kidney diseases-a narrative review. Int J Mol Sci. 2024;25(9):4959. PMID: 38732178. PMCID: PMC11084583. https://doi.org/10.3390/ijms25094959Gajewska A, Wasiak J, Sapeda N, Młynarska E, Rysz J, Franczyk B. SGLT2 inhibitors in kidney diseases-a narrative review. Int J Mol Sci. 2024;25(9):4959. PMID: 38732178. PMCID: PMC11084583. https://doi.org/10.3390/ijms25094959Rizzo MR, Di Meo I, Polito R, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022;176:106062. PMID: 35017046. https://doi.org/10.1016/j.phrs.2022.106062Rizzo MR, Di Meo I, Polito R, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022;176:106062. PMID: 35017046. https://doi.org/10.1016/j.phrs.2022.106062Sun M, Sun J, Sun W, et al. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential. Front Pharmacol. 2024;15:1369352. PMID: 38595915. PMCID: PMC11002155. https://doi.org/10.3389/fphar.2024.1369352Sun M, Sun J, Sun W, et al. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential. Front Pharmacol. 2024;15:1369352. PMID: 38595915. PMCID: PMC11002155. https://doi.org/10.3389/fphar.2024.1369352Zhou B, Shi Y, Fu R, et al. Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:907340. PMID: 35692406. PMCID: PMC9178099. https://doi.org/10.3389/fendo.2022.907340Zhou B, Shi Y, Fu R, et al. Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:907340. PMID: 35692406. PMCID: PMC9178099. https://doi.org/10.3389/fendo.2022.907340Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. https://doi.org/10.15829/1560-4071-2023-5452Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.). https://doi.org/10.15829/1560-4071-2023-5452Погосова Н.В., Бойцов С.А. Профилактическая кардиология 2024: состояние проблемы и перспективы развития. Кардиология. 2024;64(1):4–13. PMID: 38323439. https://doi.org/10.18087/cardio.2024.1.n2636Pogosova NV, Boytsov SA. Preventive cardiology 2024: state of problem perspectives of development. Kardiologiia. 2024;64(1):4–13. (In Russ.). PMID: 38323439. https://doi.org/10.18087/cardio.2024.1.n2636Eghøj M, Zinckernagel L, Brinks T, et al. Adapting an evidence-based, home cardiac rehabilitation programme for people with heart failure and their caregivers to the Danish context: DK:REACH-HF study. Eur J Cardiovasc Nurs. Published online March 25, 2024. PMID: 38526240. https://doi.org/10.1093/eurjcn/zvae037Eghøj M, Zinckernagel L, Brinks T, et al. Adapting an evidence-based, home cardiac rehabilitation programme for people with heart failure and their caregivers to the Danish context: DK:REACH-HF study. Eur J Cardiovasc Nurs. Published online March 25, 2024. PMID: 38526240. https://doi.org/10.1093/eurjcn/zvae037Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors – safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. PMID: 38789017. https://doi.org/10.1016/j.cpcardiol.2024.102664Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors – safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024;49(9):102664. PMID: 38789017. https://doi.org/10.1016/j.cpcardiol.2024.102664Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48(10):101817. PMID: 37211299. https://doi.org/10.1016/j.cpcardiol.2023.101817Cunningham C, Jabri A, Alhuneafat L, Aneja A. A comprehensive guide to sodium glucose cotransport inhibitors. Curr Probl Cardiol. 2023;48(10):101817. PMID: 37211299. https://doi.org/10.1016/j.cpcardiol.2023.101817He Z, Yang L, Nie Y, et al. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2021;345:83–88. PMID: 34653575. https://doi.org/10.1016/j.ijcard.2021.10.008He Z, Yang L, Nie Y, et al. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol. 2021;345:83–88. PMID: 34653575. https://doi.org/10.1016/j.ijcard.2021.10.008Crisman E, Duarte P, Dauden E, et al. KEAP1-NRF2 protein-protein interaction inhibitors: design, pharmacological properties and therapeutic potential. Med Res Rev. 2023;43(1):237–287. PMID: 36086898. PMCID: PMC10087726. https://doi.org/10.1002/med.21925Crisman E, Duarte P, Dauden E, et al. KEAP1-NRF2 protein-protein interaction inhibitors: design, pharmacological properties and therapeutic potential. Med Res Rev. 2023;43(1):237–287. PMID: 36086898. PMCID: PMC10087726. https://doi.org/10.1002/med.21925Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015;88(Pt B):314–336. PMID: 26066302. PMCID: PMC4628850. https://doi.org/10.1016/j.freeradbiomed.2015.05.036Zhang H, Davies KJA, Forman HJ. Oxidative stress response and Nrf2 signaling in aging. Free Radic Biol Med. 2015;88(Pt B):314–336. PMID: 26066302. PMCID: PMC4628850. https://doi.org/10.1016/j.freeradbiomed.2015.05.036Cheng PP, Wang XT, Liu Q, et al. Nrf2 mediated signaling axis in heart failure: potential pharmacological receptor. Pharmacol Res. 2024;206:107268. PMID: 38908614. https://doi.org/10.1016/j.phrs.2024.107268Cheng PP, Wang XT, Liu Q, et al. Nrf2 mediated signaling axis in heart failure: potential pharmacological receptor. Pharmacol Res. 2024;206:107268. PMID: 38908614. https://doi.org/10.1016/j.phrs.2024.107268Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36(5):924–963. PMID: 27192495. https://doi.org/10.1002/med.21396Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36(5):924–963. PMID: 27192495. https://doi.org/10.1002/med.21396Lu Y, An L, Taylor MRG, Chen QM. Nrf2 signaling in heart failure: expression of Nrf2, Keap1, antioxidant, and detoxification genes in dilated or ischemic cardiomyopathy. Physiol Genomics. 2022;54(3):115–127. https://doi.org/10.1152/physiolgenomics.00079.2021Lu Y, An L, Taylor MRG, Chen QM. Nrf2 signaling in heart failure: expression of Nrf2, Keap1, antioxidant, and detoxification genes in dilated or ischemic cardiomyopathy. Physiol Genomics. 2022;54(3):115–127. https://doi.org/10.1152/physiolgenomics.00079.2021Chen YY, Wu TT, Ho CY, et al. Blocking of SGLT2 to eliminate NADPH-induced oxidative stress in lenses of animals with fructose-induced diabetes mellitus. Int J Mol Sci. 2022;23(13):7142. PMID: 35806147. PMCID: PMC9266761. https://doi.org/10.3390/ijms23137142Chen YY, Wu TT, Ho CY, et al. Blocking of SGLT2 to eliminate NADPH-induced oxidative stress in lenses of animals with fructose-induced diabetes mellitus. Int J Mol Sci. 2022;23(13):7142. PMID: 35806147. PMCID: PMC9266761. https://doi.org/10.3390/ijms23137142Massagué J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023;186(19):4007–4037. PMID: 37714133. PMCID: PMC10772989. https://doi.org/10.1016/j.cell.2023.07.036Massagué J, Sheppard D. TGF-β signaling in health and disease. Cell. 2023;186(19):4007–4037. PMID: 37714133. PMCID: PMC10772989. https://doi.org/10.1016/j.cell.2023.07.036Hata A, Chen YG. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061. PMID: 27449815. PMCID: PMC5008074. https://doi.org/10.1101/cshperspect.a022061Hata A, Chen YG. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8(9):a022061. PMID: 27449815. PMCID: PMC5008074. https://doi.org/10.1101/cshperspect.a022061Fatehi Hassanabad A, Zarzycki A, Fedak PWM. Cellular and molecular mechanisms driving cardiac tissue fibrosis: on the precipice of personalized and precision medicine. Cardiovasc Pathol. 2024;71:107635. PMID: 38508436. https://doi.org/10.1016/j.carpath.2024.107635Fatehi Hassanabad A, Zarzycki A, Fedak PWM. Cellular and molecular mechanisms driving cardiac tissue fibrosis: on the precipice of personalized and precision medicine. Cardiovasc Pathol. 2024;71:107635. PMID: 38508436. https://doi.org/10.1016/j.carpath.2024.107635Giordano C, Francone M, Cundari G, Pisano A, d’Amati G. Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication. Cardiovasc Pathol. 2022;56:107391. PMID: 34601072. https://doi.org/10.1016/j.carpath.2021.107391Giordano C, Francone M, Cundari G, Pisano A, d’Amati G. Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication. Cardiovasc Pathol. 2022;56:107391. PMID: 34601072. https://doi.org/10.1016/j.carpath.2021.107391Gager GM, von Lewinski D, Sourij H, et al. Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure. Biomed Pharmacother. 2021;143:112169. PMID: 34560555. https://doi.org/10.1016/j.biopha.2021.112169Gager GM, von Lewinski D, Sourij H, et al. Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure. Biomed Pharmacother. 2021;143:112169. PMID: 34560555. https://doi.org/10.1016/j.biopha.2021.112169Kume S, Packer M. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney. Kidney Int. 2024;105(6):1172–1176. PMID: 38777403. https://doi.org/10.1016/j.kint.2024.01.044Kume S, Packer M. SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney. Kidney Int. 2024;105(6):1172–1176. PMID: 38777403. https://doi.org/10.1016/j.kint.2024.01.044Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383–1405. PMID: 36315602. PMCID: PMC9624240. https://doi.org/10.1161/CIRCULATIONAHA.122.061732Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146(18):1383–1405. PMID: 36315602. PMCID: PMC9624240. https://doi.org/10.1161/CIRCULATIONAHA.122.061732Stachteas P, Karakasis P, Patoulias D, Clemenza F, Fragakis N, Rizzo M. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667. PMID: 38233735. PMCID: PMC10798275. https://doi.org/10.1080/07853890.2024.2304667Stachteas P, Karakasis P, Patoulias D, Clemenza F, Fragakis N, Rizzo M. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Ann Med. 2023;55(2):2304667. PMID: 38233735. PMCID: PMC10798275. https://doi.org/10.1080/07853890.2024.2304667Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64–73. Published correction appears in Diab Vasc Dis Res. 2018;15(4):364. PMID: 28976221. https://doi.org/10.1177/1479164117733626Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64–73. Published correction appears in Diab Vasc Dis Res. 2018;15(4):364. PMID: 28976221. https://doi.org/10.1177/1479164117733626Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. PMID: 30415602. https://doi.org/10.1056/NEJMoa1812389Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. PMID: 30415602. https://doi.org/10.1056/NEJMoa1812389McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829. https://doi.org/10.1056/NEJMoa1911303McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829. https://doi.org/10.1056/NEJMoa1911303Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. PMID: 36027570. https://doi.org/10.1056/NEJMoa2206286Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. PMID: 36027570. https://doi.org/10.1056/NEJMoa2206286Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. PMID: 32970396. https://doi.org/10.1056/NEJMoa2024816Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. PMID: 32970396. https://doi.org/10.1056/NEJMoa2024816Borlaug BA, Reddy YNV, Braun A, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834–844. PMID: 37534453. PMCID: PMC10529848. https://doi.org/10.1161/CIRCULATIONAHA.123.065134Borlaug BA, Reddy YNV, Braun A, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834–844. PMID: 37534453. PMCID: PMC10529848. https://doi.org/10.1161/CIRCULATIONAHA.123.065134Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. PMID: 34711976. PMCID: PMC8604725. https://doi.org/10.1038/s41591-021-01536-xNassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960. PMID: 34711976. PMCID: PMC8604725. https://doi.org/10.1038/s41591-021-01536-xScholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440–447. PMID: 33318125. PMCID: PMC7818331. https://doi.org/10.2337/dc20-2604Scholtes RA, Muskiet MHA, van Baar MJB, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440–447. PMID: 33318125. PMCID: PMC7818331. https://doi.org/10.2337/dc20-2604Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2022;79(2):244–256.e1. PMID: 34029680. https://doi.org/10.1053/j.ajkd.2021.05.005Heerspink HJL, Oshima M, Zhang H, et al. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2022;79(2):244–256.e1. PMID: 34029680. https://doi.org/10.1053/j.ajkd.2021.05.005Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326–336. Published correction appears in Circulation. 2021;143(4):e30. PMID: 33081531. PMCID: PMC7834905. https://doi.org/10.1161/CIRCULATIONAHA.120.051783Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326–336. Published correction appears in Circulation. 2021;143(4):e30. PMID: 33081531. PMCID: PMC7834905. https://doi.org/10.1161/CIRCULATIONAHA.120.051783Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144(16):1284–1294. PMID: 34459213. PMCID: PMC8522627. https://doi.org/10.1161/CIRCULATIONAHA.121.056824Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021;144(16):1284–1294. PMID: 34459213. PMCID: PMC8522627. https://doi.org/10.1161/CIRCULATIONAHA.121.056824Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. PMID: 33200892. https://doi.org/10.1056/NEJMoa2030183Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. PMID: 33200892. https://doi.org/10.1056/NEJMoa2030183Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704. PMID: 29937267. https://doi.org/10.1016/S2213-8587(18)30141-4Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704. PMID: 29937267. https://doi.org/10.1016/S2213-8587(18)30141-4Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. PMID: 26378978. https://doi.org/10.1056/NEJMoa1504720Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. PMID: 26378978. https://doi.org/10.1056/NEJMoa1504720Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. PMID: 32966714. https://doi.org/10.1056/NEJMoa2004967Cannon CP, Pratley R, Dagogo-Jack S, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. PMID: 32966714. https://doi.org/10.1056/NEJMoa2004967Bhatt DL, Szarek M, Pitt B, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139. PMID: 33200891. https://doi.org/10.1056/NEJMoa2030186Bhatt DL, Szarek M, Pitt B, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139. PMID: 33200891. https://doi.org/10.1056/NEJMoa2030186Mansouri MH, Mansouri P, Sadeghi M, et al. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial). Clin Cardiol. 2024;47(1):e24158. PMID: 37721420. PMCID: PMC10766003. https://doi.org/10.1002/clc.24158Mansouri MH, Mansouri P, Sadeghi M, et al. Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial). Clin Cardiol. 2024;47(1):e24158. PMID: 37721420. PMCID: PMC10766003. https://doi.org/10.1002/clc.24158Xie L, Li S, Yu X, Wei Q, Yu F, Tong J. DAHOS study: efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - a 3-month, multicenter, randomized controlled clinical trial. Eur J Clin Pharmacol. 2024;80(5):771–780. PMID: 38386021. https://doi.org/10.1007/s00228-024-03643-3Xie L, Li S, Yu X, Wei Q, Yu F, Tong J. DAHOS study: efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - a 3-month, multicenter, randomized controlled clinical trial. Eur J Clin Pharmacol. 2024;80(5):771–780. PMID: 38386021. https://doi.org/10.1007/s00228-024-03643-3James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):EVIDoa2300286. PMID: 38320489. https://doi.org/10.1056/EVIDoa2300286James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):EVIDoa2300286. PMID: 38320489. https://doi.org/10.1056/EVIDoa2300286Giaccari A, Pontremoli R, Perrone Filardi P. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: a practical approach for routine clinical practice. Int J Cardiol. 2022;351:66–70. PMID: 34979145. https://doi.org/10.1016/j.ijcard.2021.12.050Giaccari A, Pontremoli R, Perrone Filardi P. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: a practical approach for routine clinical practice. Int J Cardiol. 2022;351:66–70. PMID: 34979145. https://doi.org/10.1016/j.ijcard.2021.12.050Курашин В.К., Боровкова Н.Ю., Курашина В.А., Бакка Т.Е. Возможности кардио- и нефропротективного действия препаратов группы ингибиторов SGLT2. Клиническая медицина. 2021;99(3):172–176. https://doi.org/10.30629/0023-2149-2021-99-3-172-176Kurashin VK, Borovkova NYu, Kurashina VA, Bakka TE. Possibilities of cardio- and nephroprotective effects of drugs of the SGLT2 inhibitor group. Clinical Medicine (Russian Journal). 2021;99(3):172–176. (In Russ.). https://doi.org/10.30629/0023-2149-2021-99-3-172-176Woo V, Connelly K, Lin P, McFarlane P. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Curr Med Res Opin. 2019;35(7):1283–1295. PMID: 30767677. https://doi.org/10.1080/03007995.2019.1576479Woo V, Connelly K, Lin P, McFarlane P. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes. Curr Med Res Opin. 2019;35(7):1283–1295. PMID: 30767677. https://doi.org/10.1080/03007995.2019.1576479Bülow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. J Histochem Cytochem. 2019;67(9):643–661. PMID: 31116062. PMCID: PMC6713975. https://doi.org/10.1369/0022155419849388Bülow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. J Histochem Cytochem. 2019;67(9):643–661. PMID: 31116062. PMCID: PMC6713975. https://doi.org/10.1369/0022155419849388Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. Front Endocrinol (Lausanne). 2023;14:1238927. PMID: 37600689. PMCID: PMC10433744. https://doi.org/10.3389/fendo.2023.1238927Wang Y, Jin M, Cheng CK, Li Q. Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. Front Endocrinol (Lausanne). 2023;14:1238927. PMID: 37600689. PMCID: PMC10433744. https://doi.org/10.3389/fendo.2023.1238927Sarafidis P, Ortiz A, Ferro CJ, et al; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021;39(6):1090–1097. PMID: 33443971. https://doi.org/10.1097/HJH.0000000000002776Sarafidis P, Ortiz A, Ferro CJ, et al; ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardiovascular Medicine’ (EURECA-m) working group of the European Renal Association. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J Hypertens. 2021;39(6):1090–1097. PMID: 33443971. https://doi.org/10.1097/HJH.0000000000002776Thomson SC, Vallon V. Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol. 2019;124 Suppl 1(Suppl 1):S28–S35. PMID: 31741437. PMCID: PMC7258222. https://doi.org/10.1016/j.amjcard.2019.10.027Thomson SC, Vallon V. Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol. 2019;124 Suppl 1(Suppl 1):S28–S35. PMID: 31741437. PMCID: PMC7258222. https://doi.org/10.1016/j.amjcard.2019.10.027Skrabic R, Kumric M, Vrdoljak J, et al. SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice. Biomedicines. 2022;10(10):2458. PMID: 36289720. PMCID: PMC9598622. https://doi.org/10.3390/biomedicines10102458Skrabic R, Kumric M, Vrdoljak J, et al. SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice. Biomedicines. 2022;10(10):2458. PMID: 36289720. PMCID: PMC9598622. https://doi.org/10.3390/biomedicines10102458Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732. PMID: 37240080. PMCID: PMC10218404. https://doi.org/10.3390/ijms24108732Di Costanzo A, Esposito G, Indolfi C, Spaccarotella CAM. SGLT2 inhibitors: a new therapeutical strategy to improve clinical outcomes in patients with chronic kidney diseases. Int J Mol Sci. 2023;24(10):8732. PMID: 37240080. PMCID: PMC10218404. https://doi.org/10.3390/ijms24108732Корбут А.И., Климонтов В.В. Эмпаглифлозин: новая стратегия нефропротекции при сахарном диабете. Сахарный диабет. 2017;20(1):75–84. https://doi.org/10.14341/dm8005Korbut AI, Klimontov VV. Empagliflozin: a new strategy for nephroprotection in diabetes. Diabetes Mellitus. 2017;20(1):75–84. (In Russ.). https://doi.org/10.14341/dm8005Сухарева О.Ю., Зураева З.Т., Шамхалова М.Ш. Актуализация позиций глифлозинов в алгоритмах лечения пациентов с сахарным диабетом 2 типа и хронической болезнью почек: новые патогенетические механизмы и данные субанализов крупных рандомизированных контролируемых исследований. Сахарный диабет. 2021;24(6):553–564. https://doi.org/10.14341/dm12864Sukhareva OYu, Zuraeva ZT, Shamkhalova MSh. Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails. Diabetes Mellitus. 2021;24(6):553–564. (In Russ.). https://doi.org/10.14341/dm12864Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444–2455. PMID: 37230946. PMCID: PMC10615631. https://doi.org/10.1093/ndt/gfad112Mark PB, Sarafidis P, Ekart R, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444–2455. PMID: 37230946. PMCID: PMC10615631. https://doi.org/10.1093/ndt/gfad112Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth?. Diabetes Care. 2022;45(10):e148–e149. PMID: 35973076. PMCID: PMC9862288. https://doi.org/10.2337/dc22-0921Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Activation of the tubulo-glomerular feedback by SGLT2 inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: toward the end of a myth?. Diabetes Care. 2022;45(10):e148–e149. PMID: 35973076. PMCID: PMC9862288. https://doi.org/10.2337/dc22-0921Kim NH, Kim NH. Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022;46(4):543–551. PMID: 35929172. PMCID: PMC9353563. https://doi.org/10.4093/dmj.2022.0209Kim NH, Kim NH. Renoprotective mechanism of sodium-glucose cotransporter 2 inhibitors: focusing on renal hemodynamics. Diabetes Metab J. 2022;46(4):543–551. PMID: 35929172. PMCID: PMC9353563. https://doi.org/10.4093/dmj.2022.0209Wang Q, Yu J, Deng W, et al. Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis. Front Pharmacol. 2024;15:1372421. PMID: 38983922. PMCID: PMC11231204. https://doi.org/10.3389/fphar.2024.1372421Wang Q, Yu J, Deng W, et alInfluence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis. Front Pharmacol. 2024;15:1372421. PMID: 38983922. PMCID: PMC11231204. https://doi.org/10.3389/fphar.2024.1372421Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29(2):190–198. PMID: 31815757. PMCID: PMC7224333. https://doi.org/10.1097/MNH.0000000000000584Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29(2):190–198. PMID: 31815757. PMCID: PMC7224333. https://doi.org/10.1097/MNH.0000000000000584Cleveland KH, Schnellmann RG. Pharmacological targeting of mitochondria in diabetic kidney disease. Pharmacol Rev. 2023;75(2):250–262. PMID: 36781216. https://doi.org/10.1124/pharmrev.122.000560Cleveland KH, Schnellmann RG. Pharmacological targeting of mitochondria in diabetic kidney disease. Pharmacol Rev. 2023;75(2):250–262. PMID: 36781216. https://doi.org/10.1124/pharmrev.122.000560Mulder S, Heerspink HJL, Darshi M, et al. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes Obes Metab. 2019;21(11):2422–2428. PMID: 31264758. https://doi.org/10.1111/dom.13823Mulder S, Heerspink HJL, Darshi M, et al. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes Obes Metab. 2019;21(11):2422–2428. PMID: 31264758. https://doi.org/10.1111/dom.13823Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol. 2019;317(4):F767–F780. PMID: 31390268. https://doi.org/10.1152/ajprenal.00565.2018Lee YH, Kim SH, Kang JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am J Physiol Renal Physiol. 2019;317(4):F767–F780. PMID: 31390268. https://doi.org/10.1152/ajprenal.00565.2018Chun Y, Kim J. AMPK-mTOR signaling and cellular adaptations in hypoxia. Int J Mol Sci. 2021;22(18):9765. PMID: 34575924. PMCID: PMC8465282. https://doi.org/10.3390/ijms22189765Chun Y, Kim J. AMPK-mTOR signaling and cellular adaptations in hypoxia. Int J Mol Sci. 2021;22(18):9765. PMID: 34575924. PMCID: PMC8465282. https://doi.org/10.3390/ijms22189765Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023;11(2):279. PMID: 36830815. PMCID: PMC9953060. https://doi.org/10.3390/biomedicines11020279Podestà MA, Sabiu G, Galassi A, Ciceri P, Cozzolino M. SGLT2 inhibitors in diabetic and non-diabetic chronic kidney disease. Biomedicines. 2023;11(2):279. PMID: 36830815. PMCID: PMC9953060. https://doi.org/10.3390/biomedicines11020279Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020;13(5):728–733. PMID: 33123352. PMCID: PMC7577767. https://doi.org/10.1093/ckj/sfaa198Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020;13(5):728–733. PMID: 33123352. PMCID: PMC7577767. https://doi.org/10.1093/ckj/sfaa198Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. PMID: 28605608. https://doi.org/10.1056/NEJMoa1611925Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. PMID: 28605608. https://doi.org/10.1056/NEJMoa1611925Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. PMID: 32865377. https://doi.org/10.1056/NEJMoa2022190Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. PMID: 32865377. https://doi.org/10.1056/NEJMoa2022190Chang YK, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11(7):e0158810. Published correction appears in PLoS One. 2016;11(7):e0160478. PMID: 27391020. PMCID: PMC4938401. https://doi.org/10.1371/journal.pone.0158810Chang YK, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11(7):e0158810. Published correction appears in PLoS One. 2016;11(7):e0160478. PMID: 27391020. PMCID: PMC4938401. https://doi.org/10.1371/journal.pone.0158810Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–535. PMID: 30045814. https://doi.org/10.1016/j.kint.2018.05.002Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524–535. PMID: 30045814. https://doi.org/10.1016/j.kint.2018.05.002

The authors declare that there are no conflicts of interest present.